Home
Categories
Immuno-Oncology
Therapies
- Approved Drugs
- Experimental Therapies
  - a
  - b-c
  - D-F
  - G-I
    - GALE-301
    - Galinpepimut-S
    - Ganitumab
    - GBR 1342
    - GI-6207
    - GI-6301
    - GL-ONC1
    - Gliovac (ERC1671)
    - GP2
    - GRN-1201
    - GSK3174998
    - GWN323
    - HF10
    - ICT-107
    - ICT-121
    - IGN002
    - IMCgp100
    - IMP701
    - INCAGN1949
    - INO-1400
    - INO-3106
    - INO-5150
    - INO-9012
  - J-L
  - M-O
    - M7824
    - MAGE-A10 T-Cell Therapy
    - MBG453
    - MDNA55
    - MEDI0457
    - MEDI0562
    - MEDI0680
    - MGA012
    - MGD009
    - MK-4166
    - Mogamulizumab
    - MVA-BN Brachyury
    - MVI-118
    - NEO-PV-01
    - NeuVax (Nelipepimut-S)
    - NKR-2
    - NKTR-214
    - NY-ESO TCR
    - OncoVAX
    - ONCOS-102
  - P-S
    - PAN-301-1
    - PDR001
    - PDS0101
    - PF-04518600
    - PF-06801591
    - PNK-007
    - ProscaVax
    - Provenge (Sipuleucel-T)
    - PVRIG
    - REGN2810 (SAR439684)
    - REGN3767
    - Relatlimab
    - Reolysin
    - RG7802
    - RG7828
    - Rocapuldencel-T
    - rSIFN-co
    - SHR-1210
    - SL-701
    - SurVaxM
  - T-Z
    - TT12
    - Tedopi (OSE-2101)
    - Telomelysin (OBP-301)
    - TG4010
    - TPIV 200
    - TPIV200
    - Traumakine
    - TRX518
    - TSR-022
    - TSR-042
    - Utomilumab
    - ValloVax
    - Varlilumab
    - VBI-1901
    - VGX-3100
    - Viagenpumatucel-L
    - Vigil
    - VX15
    - XmAb13676
COVID-19 Info
- COVID-19 Updates

Search for:

Immunotherapy

June 15, 2017June 15, 2017

First Patient Dosed in Immunotherapy Combo Trial of Yervoy, Evofosfamide in Solid Tumors

Immunotherapy, News

The first patient has been dosed in a Phase 1 clinical trial evaluating the immunotherapy combination of Threshold Pharmaceuticals‘ evofosfamide (TH-302) plus Bristol-Myers Squibb‘s Yervoy (ipilimumab) for the treatment of patients with advanced solid ... Read more

Search for:

Featured Posts

FDA Approves Bavencio Maintenance Therapy for Advanced Bladder Cancer

July 2, 2020

FDA Approves Keytruda as First-line Therapy for Certain Advanced Colorectal Cancers

July 1, 2020

FDA’s New ‘Project Patient Voice’ to Share Symptoms Data From Cancer Trials

June 30, 2020

Visit Immuno-Oncology News's profile on Pinterest.

Bionews, Inc.

3 W Garden St
Suite 700
Pensacola, FL 32502
Email: [email protected]
Phone: +1-800-936-1363

Publishing Team
Leadership
Our Values
Corrections Policy
Contact Us
Terms of Service
Privacy Policy

Disclaimer:

Immuno-Oncology News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

We use cookies to enhance your experience on our website. Privacy PolicyAccept